NASDAQ:LSTA Lisata Therapeutics Q4 2025 Earnings Report $1.67 -0.45 (-21.23%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.72 +0.05 (+2.99%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Lisata Therapeutics EPS ResultsActual EPS-$0.33Consensus EPS -$0.74Beat/MissBeat by +$0.41One Year Ago EPSN/ALisata Therapeutics Revenue ResultsActual Revenue$0.10 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALisata Therapeutics Announcement DetailsQuarterQ4 2025Date3/12/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsLisata Therapeutics' next earnings date is estimated for Thursday, August 6, 2026, based on past reporting schedules. Conference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Lisata Therapeutics Earnings HeadlinesLisata Therapeutics (NASDAQ:LSTA) Trading Down 3.6% - Should You Sell?July 24 at 2:21 AM | americanbankingnews.comLisata Therapeutics stock falls after hours: Here's whyJuly 23 at 7:33 AM | msn.comALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's latest AI patent as the catalyst behind their next major call. They say a market pattern with a 100% historical track record is converging with this new breakthrough by end of month. The last time conditions aligned like this, investors had the chance to turn $10,000 into as much as $350,000 in roughly 12 months. Brown and Chaikin have released the full details for investors who want to get ahead of it.July 26 at 1:00 AM | Brownstone Research (Ad)Lisata Therapeutics Extends Merger Timeline with Kuva LabsJuly 17, 2026 | tipranks.comJohnson Fistel Investigates Lisata Therapeutics, Inc. (LSTA) After Disclosures Concerning Acquisition FinancingJune 26, 2026 | globenewswire.comLisata Therapeutics, Inc.: Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.June 10, 2026 | finanznachrichten.deSee More Lisata Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lisata Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lisata Therapeutics and other key companies, straight to your email. Email Address About Lisata TherapeuticsLisata Therapeutics (NASDAQ:LSTA) (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches. Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies. To advance its programs, the company collaborates with academic institutions and contract research organizations, supporting clinical studies and translational research efforts in North America and Europe. Headquartered in the United States, Lisata Therapeutics is governed by a leadership team with experience in biotechnology research, clinical operations and regulatory affairs. The company’s board and scientific advisors bring expertise in immunology, drug development and commercial strategy to support its mission of addressing unmet medical needs.View Lisata Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/20- 07/24Telecom Earnings Reveal a Sector That Finally Looks HealthierAMD and Cerbras Create A New Blueprint For HardwareIntel Earnings Reveal Whether the Chip Selloff Created a BuyRTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?Broadcom May Be the Biggest Winner From Alphabet's EarningsDefense Earnings Show Readiness Now and Modernization Ahead Upcoming Earnings Nucor (7/27/2026)Cadence Design Systems (7/27/2026)Coca Cola Femsa (7/27/2026)Welltower (7/27/2026)Astrazeneca (7/27/2026)PACCAR (7/28/2026)Ford Motor (7/28/2026)Boeing (7/28/2026)Ecolab (7/28/2026)Rio Tinto (7/28/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
